Management of psoriasis
Date: 23 April 2021
Psoriasis is a complex inflammatory condition that is characterised by the development of red, scaly areas of skin, and which often is accompanied with pain and inflammation of the joints.
The symptoms of psoriasis, along with its chronic and relapsing frequency, can cause considerable physical discomfort for patients, as well as having significant psychosocial impacts.
Apremilast is an oral prescription medicine indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.1
It is available under the brand name Otezla®.
Guild Learning and Development has partnered with Amgen in the development of a new online course titled Otezla® (apremilast) for the management of psoriasis.
The course updates pharmacists on the symptoms, prevalence and burden of psoriasis, including the impact on quality of life and mental health of people who have the condition.
It looks at the best-practice management of psoriasis, with a focus on the use of Otezla® (apremilast) in plaque psoriasis.
Guild Learning and Development thanks Amgen for its financial support and subject matter expertise in developing this module.
This activity has been accredited for 1 hours of Group 1 CPD (or 1 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 1 hours of Group 2 CPD (or 1.5 CPD credits) upon successful completion of relevant assessment activities.
- Amgen. Australian Product Information - Otezla (aprelimast). 2020
Contact: Peter Waterman
Phone: 0419 260 827
Page last updated on: 18 January 2022